Chen Xun, Miao Huamao, Li Boliang, Cheng Mingrui, Lin I-Chun, Lei Yadi, Jiang Yinjie, Wang Xiaoying, Zhou Xingtao
Eye Ear Nose and Throat Hospital, Fudan University, No. 19 BaoQing Road, XuHui District, Shanghai, 200031, China.
National Health Commission Key Lab of Myopia, Fudan University, Shanghai, China.
BMC Ophthalmol. 2025 Mar 17;25(1):138. doi: 10.1186/s12886-025-03932-0.
To evaluate changes in intraocular, corneal, and whole-eye higher-order aberrations (HOAs) after EVO intraocular collamer lens (ICL) implantation.
In this retrospective study, we enrolled 53 eyes of 53 patients and measured their refractive parameters and intraocular, corneal, and whole-eye HOAs using OPD scanning preoperatively and 1 month, and 3 years postoperatively. All statistical analyses were performed using SPSS software.
The safety index was 1.31 ± 0.15, and the efficacy index was 1.02 ± 0.24 3 years postoperatively. The best linear fit curve of the attempted versus achieved correction was y = 0.96x + 0.08 at 3 years postoperatively. The mean spherical equivalent decreased from - 8.53 ± 2.49 D preoperatively to -0.09 ± 0.25 D and - 0.34 ± 0.41 D at 1 month and 3 years postoperatively, respectively (P < 0.05). The whole-eye trefoil and total HOAs, intraocular trefoil, corneal trefoil increased significantly at 1 month (P < 0.05) but did not change significantly at 3 years (P > 0.05) postoperatively compared to the preoperative value. The intraocular spherical aberration and total HOAs increased significantly at 1 month and 3 years postoperatively (P < 0.05). The whole-eye coma or spherical aberration, intraocular coma, corneal coma or spherical aberration or total HOAs did not differ from those observed at 1 month and 3 years postoperatively (P > 0.05).
Long-term EVO-ICL implantation is safe, effective, predictable, and stable. The intraocular and corneal trefoils increased significantly in the early postoperative period but can be recovered to the preoperative level in the long term. The intraocular spherical aberration increases slightly in the long term postoperatively, but the whole-eye spherical aberration does not change significantly.
评估EVO人工晶状体（ICL）植入术后眼内、角膜及全眼高阶像差（HOAs）的变化。
在这项回顾性研究中，我们纳入了53例患者的53只眼，术前、术后1个月和3年使用OPD扫描测量其屈光参数以及眼内、角膜和全眼的高阶像差。所有统计分析均使用SPSS软件进行。
术后3年安全指数为1.31±0.15，有效指数为1.02±0.24。术后3年，预期矫正与实际矫正的最佳线性拟合曲线为y = 0.96x + 0.08。等效球镜度均值术前为-8.53±2.49 D，术后1个月和3年分别降至-0.09±0.25 D和-0.34±0.41 D（P < 0.05）。与术前相比，全眼三叶像差和总高阶像差、眼内三叶像差、角膜三叶像差在术后1个月显著增加（P < 0.05），但术后3年无显著变化（P > 0.05）。眼内球差和总高阶像差在术后1个月和3年显著增加（P < 0.05）。全眼彗差或球差、眼内彗差、角膜彗差或球差或总高阶像差在术后1个月和3年无差异（P > 0.05）。
长期植入EVO-ICL安全、有效、可预测且稳定。术后早期眼内和角膜三叶像差显著增加，但长期可恢复至术前水平。术后长期眼内球差略有增加，但全眼球差无显著变化。
